AnaptysBio (NASDAQ:ANAB) Shares Gap Up – What’s Next?

AnaptysBio, Inc. (NASDAQ:ANAB) shares gapped up before the market opened on Monday . The stock had previously closed at $17.08, but opened at $18.01. AnaptysBio shares last traded at $19.49, with a volume of 220,227 shares traded.

Analyst Upgrades and Downgrades

ANAB has been the subject of a number of research reports. Wolfe Research initiated coverage on AnaptysBio in a report on Tuesday, February 4th. They set an “outperform” rating and a $25.00 target price for the company. HC Wainwright reissued a “neutral” rating and set a $22.00 target price on shares of AnaptysBio in a report on Tuesday, March 4th. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Truist Financial dropped their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Finally, Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a research note on Monday, March 3rd. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $35.11.

AnaptysBio Price Performance

The stock has a 50-day simple moving average of $16.80 and a 200-day simple moving average of $22.47. The stock has a market cap of $581.42 million, a P/E ratio of -3.12 and a beta of 0.02.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.89. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $43.11 million for the quarter, compared to analysts’ expectations of $10.17 million. As a group, sell-side analysts forecast that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the transaction, the director now directly owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 33.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ANAB. Tower Research Capital LLC TRC grew its holdings in shares of AnaptysBio by 131.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 1,531 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of AnaptysBio during the fourth quarter worth about $40,000. AlphaQuest LLC grew its holdings in shares of AnaptysBio by 1,891.5% during the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 4,237 shares during the last quarter. Virtus ETF Advisers LLC grew its holdings in shares of AnaptysBio by 24.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 936 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of AnaptysBio by 1,585.8% during the fourth quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company’s stock worth $75,000 after purchasing an additional 5,360 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.